ClinicalTrials.gg
RecruitingNCT06168058EMBOLIZEUpdated Oct 16, 2026

Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices

An interventional study of Transcatheter Venography and Bilateral ovarian vein embolization in Chronic Pelvic Pain Syndrome, Pelvic Pain and Pelvic Varices, sponsored by Weill Medical College of Cornell University. Recruiting at 5 sites in United States. Open to female participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 16, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 152 studies in Pelvic Pain with a site in United States — 37 open to participants now, 40 under way, 1 of them phase 3. Pelvic Pain · United States.

Planned enrollment
68th of 124
40 · median 50
Started
2025
with 11 others
No phase
72 of 152
23 open now
Primary completion
2027-06
later than 16 of 39 live
Registered
121st of 152
by date

Among the 152 studies in Pelvic Pain with a site in United States, this one is the 68th largest by planned enrollment of the 124 interventional ones that give a count, is one of 12 that started in 2025, is one of 72 with no phase, reaches primary completion later than 16 of the 39 other live ones, and was the 121st registered.

Pelvic Pain

377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.

Browse Pelvic Pain studies →

Open to participants now

37 of the 152 studies in Pelvic Pain with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Pelvic Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to see if a randomized controlled trial of ovarian vein and pelvic vein embolization versus venography alone could determine outcomes for women with chronic pelvic pain and pelvic varicose veins.

The data gathered will assist in addressing changes in quality of life in patients who have ovarian/pelvic vein embolization versus no embolization.

Read the detailed description

The study is a randomized research trial of bilateral ovarian vein embolization (OVE) and pelvic vein embolization (PVE) in women with chronic pelvic pain (CPP), dilated and incompetent ovarian veins ≥6mm and pelvic varices (≥1 veins, >5 mm diameter) to assess for change in pain. Pain will be assessed by visual analog scale (VAS) and other relevant, validated quality of life metrics including the Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank v.1.0 - Pain Intensity, Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.2 - Global Health, Patient Global Impression of Change (PGIC) and EuroQol five-dimension (EQ 5D). The target population includes women age greater than or equal to 18 years who are pre-menopausal and have symptoms, and clinical and imaging findings corresponding to Pelvic Venous Disease (PeVD). Subjects will be randomized in a 1:1 fashion to embolization (treatment group) or venography only (control group). Follow-up will be assessed weekly and at 1, and 3 months and 6 months post procedure to assess for changes in quality of life in patients who receive ovarian/pelvic vein embolization versus no embolization.

03

Conditions studied

  • Chronic Pelvic Pain Syndrome
  • Pelvic Pain
  • Pelvic Varices
  • Pelvic Congestive Syndrome
  • Pelvic Pain Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of venous origin chronic pelvic pain for greater than 6 months (VAS ≥7 as determined by 4 consecutive weeks of baseline self-assessments) despite non-vascular therapy as delineated by the following criteria:

    • Pain exacerbated by walking, standing or lifting
    • Symptoms are at least partially alleviated by lying down
    • Prolonged post-coital ache
    • Absence of non-venous origin CPP as determined by Gynecology examination
  2. Symptoms-Varices-Pathophysiology Classification18 including of one of the following:

    •S2V2PBGV,R,NT, S2V2PRGV,R,NT , S2V2PLGV,R,NT, with or without S2V2 PBIIV,R,NT, S2V2 PLIIV,R,NT, S2V2 PRIIV,R,NT

  3. CT, TAUS and diagnostic venography (if needed) imaging review for pelvic venous imaging factors

    • Left or right ovarian vein diameter greater than or equal to 6 mm as documented by TAUS or CT
    • Presence of intrabdominal/pelvic varices as documented by TAUS or CT (≥1 veins, >5 mm diameter)
    • Presence of venous reflux in ovarian and/or internal iliac veins without evidence of hemodynamically significant stenosis

Exclusion criteria

Exclusion Criteria:

  • Female \<18 years of age
  • Pregnancy (positive pregnancy test)
  • Female subject who plans to become pregnant during study period
  • Female subject who is actively breastfeeding
  • Patient who is or anovulatory with hormone suppression
  • History of prior hysterectomy
  • Prior ovarian vein embolization or ovarian vein ligation
  • Inability to tolerate endovascular procedure due to acute illness or general health
  • Planned simultaneous treatment with nerve blocks during the duration of the study
  • Laparoscopy or planned surgical intervention during the duration of the study
  • Known allergy to sclerosant, coil, stent or catheter components including nickel allergy
  • Any iliac vein stenosis determined identified by the investigator on pelvic DUS, CT venogram, and/or Catheter Venography and deemed significant for exclusion by study patient review committee.
  • Any renal vein stenosis with resultant renal hilar varices/collaterals and lumbar collaterals identified by the investigator on pelvic DUS, CT venogram, and/or Diagnostic Venography and deemed significant for exclusion by study patient review committee.
  • Presence of isolated extra-pelvic vulvar and/or lower extremity varices without intrabdominal pelvic varices. Primary S3 categorization study exclusion.
  • Serious medical conditions that might preclude full participation in the study to the desired endpoint (e.g., uncontrolled diabetes, , , MI, CHF, etc.)
  • Severe allergy to iodinated or gadolinium-based contrast to premedication
  • Severe renal impairment (on chronic dialysis or estimated \<30 mL/min)
  • \<8.0 g/dL, uncorrectable >3.0 or count \<75,000/microliter
  • Inability to provide or to comply with study assessments
  • Post thrombotic IVC, iliac or ovarian vein changes
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Sham comparator
    Transcatheter Venography

    Diagnostic Test: Transcatheter Venography

  • Experimental
    Bilateral Ovarian Vein Embolization

    Transcatheter Venography plus Bilateral Ovarian Vein Embolization.

    Diagnostic Test: Transcatheter Venography · Procedure: Bilateral ovarian vein embolization

Interventions

  • Diagnostic testTranscatheter Venography

    Venographic assessment of ovarian veins and internal iliac veins

    Also known as: Diagnostic Venography

  • ProcedureBilateral ovarian vein embolization

    Intervention will include sclerosis of pelvic varices and coil embolization of the bilateral ovarian veins.

    Also known as: Ovarian vein and pelvic vein embolization

06

What researchers measure

Primary outcomes

  1. Change in Visual Analog Scale (VAS) for pelvic pain

    The VAS pain score is a standard scale from 0 to 10, defining 0 as ''no pain'' and 10 ''worst pain possible.''

    Time frame: Weekly for 4 weeks prior to Day 1 and at 30, 90 and 180 day follow up

Secondary outcomes

  1. Change in Patient-Reported Outcomes Measurement Information System (PROMIS) 3A Pain Intensity Scale

    The Patient-Reported Outcomes Measurement Information System (PROMIS) 3A Pain Intensity Scale assess how much a person hurts. The scale ranges from 1-5, defining 1 as ''no pain'' and 5 ''very severe pain.''

    Time frame: Weekly for 4 weeks prior to Day 1 and at 30, 90 and 180 day follow up

  2. Change in Patient-Reported Outcomes Measurement Information System (PROMIS) 10 Pain Intensity Scale

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health measures assess an individual's physical, mental, and social health. The scale scores from from 5 to 1 with 5 = "Excellent" and 1= "Poor ".

    Time frame: Weekly for 4 weeks prior to Day 1 and at 30, 90 and 180 day follow up

  3. Change in Patient Global Impression of Change (PGIC)

    The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale with 1= "Very Much Improved" and 7= "Very Much Worse".

    Time frame: 30, 90 and 180 day follow up

  4. Change in EuroQol five-dimension (EQ-5D) scale

    The EuroQol five-dimension (EQ-5D) is a concise, generic measure of self-reported health at each visit. Patients will tick the one box that best describes their health on that day. This scale will measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.The scale is numbered from 0 to 100. =100 means the best health the patient can imagine and 0 means the worst health the patient can imagine,.

    Time frame: Weekly for 4 weeks prior to Day 1. Then at 30, 90 and 180 day follow up

07

Study locations

4 of 5 sites recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Recruiting
    • Adam Alli, MD · Principal investigator
  • Northwell Health Physician Partners Vascular Surgery
    New Hyde Park, New York 11042, United States
    Recruiting
  • Weill Cornell Medicine
    New York, New York 10024, United States
    Recruiting
    • Neil K Khilnani, MD · Principal investigator
  • UNC School of Medicine
    Chapel Hill, North Carolina 27599, United States
    Recruiting
    • Gloria Salazar, MD · Principal investigator
  • Lake Washington Vascular
    Bellevue, Washington 98004, United States
    Withdrawn

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.

Of 110 non-industry interventional studies with no phase under Pelvic Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 20 months is above that.

Counting every sponsor, half of 114 studies reached it within 17 months; a quarter within 5 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Dec 13, 2023
StartActual
Oct 29, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • University of Kansas Medical Center · Kansas City, United States
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    1 site added
    Show site
    • University of Kansas Medical Center · Kansas City, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06168058
Collaborators
Society of Interventional Radiology Foundation, VIVA Physicians, Penumbra Inc.
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Oct 29, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Neil M Khilnani, MD
Contact
EMBOLIZE@med.cornell.edu
646-962-9179
Sasha Garcia
Contact
sag2958@med.cornell.edu
Neil M Khilnani, MD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion